182 related articles for article (PubMed ID: 18608912)
41. Antibody-mediated effects against Cryptococcus neoformans: evidence for interdependency and collaboration between humoral and cellular immunity.
Vecchiarelli A; Casadevall A
Res Immunol; 1998; 149(4-5):321-33; discussion 500-3. PubMed ID: 9720950
[No Abstract] [Full Text] [Related]
42. Therapeutic efficacy of a conjugate vaccine containing a peptide mimotope of cryptococcal capsular polysaccharide glucuronoxylomannan.
Datta K; Lees A; Pirofski LA
Clin Vaccine Immunol; 2008 Aug; 15(8):1176-87. PubMed ID: 18524882
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of Cryptococcus neoformans galactoxylomannan-protein conjugate as vaccine candidate against murine cryptococcosis.
Chow SK; Casadevall A
Vaccine; 2011 Feb; 29(10):1891-8. PubMed ID: 21238568
[TBL] [Abstract][Full Text] [Related]
44. Effect of antibody to capsular polysaccharide on eosinophilic pneumonia in murine infection with Cryptococcus neoformans.
Feldmesser M; Kress Y; Casadevall A
J Infect Dis; 1998 Jun; 177(6):1639-46. PubMed ID: 9607844
[TBL] [Abstract][Full Text] [Related]
45. [Pathogenesis, immunobiology and epidemiology of cryptococcosis].
Müller J
Mycoses; 1994; 37 Suppl 1():34-42. PubMed ID: 7854364
[TBL] [Abstract][Full Text] [Related]
46. Serum antibody response to Cryptococcus neoformans in cats, dogs and koalas with and without active infection.
Malik R; Speed BR; Kaldor J; Cairns B; Pegorer M; Wigney DI; Love DN
Med Mycol; 1999 Feb; 37(1):43-51. PubMed ID: 10200933
[TBL] [Abstract][Full Text] [Related]
47. Serologic evidence for reactivation of cryptococcosis in solid-organ transplant recipients.
Saha DC; Goldman DL; Shao X; Casadevall A; Husain S; Limaye AP; Lyon M; Somani J; Pursell K; Pruett TL; Singh N
Clin Vaccine Immunol; 2007 Dec; 14(12):1550-4. PubMed ID: 17959819
[TBL] [Abstract][Full Text] [Related]
48. Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.
Mitchell TG; Perfect JR
Clin Microbiol Rev; 1995 Oct; 8(4):515-48. PubMed ID: 8665468
[TBL] [Abstract][Full Text] [Related]
49. The heat shock protein (Hsp) 70 of Cryptococcus neoformans is associated with the fungal cell surface and influences the interaction between yeast and host cells.
Silveira CP; Piffer AC; Kmetzsch L; Fonseca FL; Soares DA; Staats CC; Rodrigues ML; Schrank A; Vainstein MH
Fungal Genet Biol; 2013 Nov; 60():53-63. PubMed ID: 23954835
[TBL] [Abstract][Full Text] [Related]
50. Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan.
Houpt DC; Pfrommer GS; Young BJ; Larson TA; Kozel TR
Infect Immun; 1994 Jul; 62(7):2857-64. PubMed ID: 8005676
[TBL] [Abstract][Full Text] [Related]
51. Towards a vaccine for Cryptococcus neoformans: principles and caveats.
Datta K; Pirofski LA
FEMS Yeast Res; 2006 Jun; 6(4):525-36. PubMed ID: 16696648
[TBL] [Abstract][Full Text] [Related]
52. Immunity in cryptococcosis: an overview.
Fromtling RA; Shadomy HJ
Mycopathologia; 1982 Mar; 77(3):183-90. PubMed ID: 7040977
[TBL] [Abstract][Full Text] [Related]
53. Production, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharide.
Dromer F; Salamero J; Contrepois A; Carbon C; Yeni P
Infect Immun; 1987 Mar; 55(3):742-8. PubMed ID: 3546139
[TBL] [Abstract][Full Text] [Related]
54. [Detection of capsular polysaccharide antigen of Cryptococcus neoformans in patients with AIDS and neurocryptococcosis in São Paulo, Brazil].
Calvo B; Fischman O; Castelo Filho A; Reis Filho J; Del Bianco R; Barbosa RM; Zaror L
Rev Inst Med Trop Sao Paulo; 1991; 33(6):485-90. PubMed ID: 1844979
[TBL] [Abstract][Full Text] [Related]
55. Cryptococcus neoformans infection can elicit protective antibodies in mice.
Mukherjee J; Scharff MD; Casadevall A
Can J Microbiol; 1994 Oct; 40(10):888-92. PubMed ID: 8000967
[TBL] [Abstract][Full Text] [Related]
56. Roles for CD40, B7 and major histocompatibility complex in induction of enhanced immunity by cryptococcal polysaccharide-pulsed antigen-presenting cells.
Blackstock R
Immunology; 2003 Feb; 108(2):158-66. PubMed ID: 12562324
[TBL] [Abstract][Full Text] [Related]
57. Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice.
Mukherjee S; Lee S; Mukherjee J; Scharff MD; Casadevall A
Infect Immun; 1994 Mar; 62(3):1079-88. PubMed ID: 8112842
[TBL] [Abstract][Full Text] [Related]
58. A proteomic-based approach for the identification of immunodominant Cryptococcus neoformans proteins.
Young M; Macias S; Thomas D; Wormley FL
Proteomics; 2009 May; 9(9):2578-88. PubMed ID: 19343717
[TBL] [Abstract][Full Text] [Related]
59. Serum antibody response to active infection with Cryptococcus neoformans and its varieties in immunocompetent subjects.
Speed BR; Kaldor J; Cairns B; Pegorer M
J Med Vet Mycol; 1996; 34(3):187-93. PubMed ID: 8803799
[TBL] [Abstract][Full Text] [Related]
60. Contribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan.
Duro RM; Netski D; Thorkildson P; Kozel TR
Clin Diagn Lab Immunol; 2003 Mar; 10(2):252-8. PubMed ID: 12626451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
